Samsung Bioepis Also Faces 2029 Wait For US Etanercept Biosimilar
New Jersey Court Enters Permanent Injunction Against Korean Firm
Samsung Bioepis’ etanercept biosimilar, freely available in Europe, will not be sold in the US until patent expiry in 2029 following action by a US district court.
